Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
- PMID: 32587641
- PMCID: PMC7308913
- DOI: 10.18549/PharmPract.2020.2.1803
Inpatient prescribing of dual antiplatelet therapy according to the guidelines: a prospective intervention study
Abstract
Background: In dual antiplatelet therapy (DAPT), low-dose acetylsalicylic acid is combined with a P2Y12 inhibitor. However, combining antithrombotic agents increases the risk of bleeding. Guidelines on DAPT recommend using this combination for a limited period of between three weeks and 30 months. This implies the risk of DAPT being erroneously continued after the intended stop date.
Objective: The primary objective of this study is to assess the proportion of hospitalized patients treated with DAPT whose treatment deviated erroneously and unintentionally from the guidelines. We also assessed risk factors and the effect of a pharmacist intervention.
Methods: All patients admitted to the Spaarne Gasthuis (Haarlem/ Hoofddorp, the Netherlands) who used DAPT between March 25th, 2019, and June 14th, 2019, were, in addition to receiving regular care, reviewed to assess whether their therapy was in line with the guidelines' recommendation and whether deviations were unintended and erroneous. In the event of an unintended deviation, the pharmacist intervened by contacting the prescriber by phone and giving advice to adjust the antithrombotic therapy in line with the guideline.
Results: We included 411 patients, of whom 21 patients (5.1%) had a treatment that deviated from the guidelines. For 11 patients (2.7%), the deviation was unintended and erroneous. The major risk factor for erroneous deviation was the use of DAPT before hospital admission (OR 18.7; 95%CI 4.79-72.7). In patients who used DAPT before admission, 18 out of 58 (31.0%) had a deviation from the guidelines of whom 8 (13.8%) were erroneous. For these eight patients, the pharmacist contacted the prescriber, and in these cases the therapy was adjusted in line with the guidelines.
Conclusions: Adherence to the guidelines recommending DAPT was high within the hospital. However, patients who used DAPT before hospital admission had a higher risk of erroneous prescription of DAPT. Intervention by a pharmacist increased adherence to guidelines and may reduce the number of preventable bleeding cases.
Keywords: Clinical Audit; Fibrinolytic Agents; Guideline Adherence; Hemorrhage; Medication Errors; Netherlands; Pharmacists; Platelet Aggregation Inhibitors; Risk Factors.
Copyright: © Pharmacy Practice and the Authors.
Conflict of interest statement
CONFLICT OF INTEREST None of the authors has any conflict of interest.
Similar articles
-
Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention study.Eur J Clin Pharmacol. 2021 Dec;77(12):1919-1926. doi: 10.1007/s00228-021-03185-y. Epub 2021 Jul 28. Eur J Clin Pharmacol. 2021. PMID: 34319470 Free PMC article.
-
Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial.JAMA. 2019 Jun 25;321(24):2428-2437. doi: 10.1001/jama.2019.8146. JAMA. 2019. PMID: 31237645 Free PMC article. Clinical Trial.
-
Persistence with dual antiplatelet therapy after percutaneous coronary intervention for ST-segment elevation acute coronary syndrome: a population-based cohort study in Catalonia (Spain).BMJ Open. 2019 Jul 23;9(7):e028114. doi: 10.1136/bmjopen-2018-028114. BMJ Open. 2019. PMID: 31340964 Free PMC article.
-
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials.Eur Heart J. 2021 Jan 21;42(4):308-319. doi: 10.1093/eurheartj/ehaa739. Eur Heart J. 2021. PMID: 33284979
-
[Dual antiplatelet therapy after acute coronary syndrome or percutaneous coronary intervention: with what and for how long?].Internist (Berl). 2021 Nov;62(11):1243-1252. doi: 10.1007/s00108-021-01189-5. Epub 2021 Oct 11. Internist (Berl). 2021. PMID: 34633479 Review. German.
Cited by
-
Implementation of a Patient Questionnaire in Community Pharmacies to Improve Care for Patients Using Combined Antithrombotic Therapy: A Qualitative Study.Pharmacy (Basel). 2023 Apr 27;11(3):80. doi: 10.3390/pharmacy11030080. Pharmacy (Basel). 2023. PMID: 37218962 Free PMC article.
-
Exploring the pharmacists' role in optimising antithrombotic therapy in primary care: a qualitative study.BMJ Open. 2024 Mar 19;14(3):e079018. doi: 10.1136/bmjopen-2023-079018. BMJ Open. 2024. PMID: 38508648 Free PMC article.
-
Guideline Adherence As An Indicator of the Extent of Antithrombotic Overuse and Underuse: A Systematic Review.Glob Heart. 2022 Aug 12;17(1):55. doi: 10.5334/gh.1142. eCollection 2022. Glob Heart. 2022. PMID: 36051325 Free PMC article.
-
Quality of acute ischemic stroke care at a tertiary Hospital in Ghana.BMC Neurol. 2022 Jan 17;22(1):28. doi: 10.1186/s12883-021-02542-9. BMC Neurol. 2022. PMID: 35039001 Free PMC article.
References
-
- Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. Guidelines for the Early Management of Patients With Acute Ischemic Stroke:2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344–e418. doi: 10.1161/str.0000000000000211. - DOI - PubMed
-
- Federatie Medisch Specialisten. [accessed Aug 18 2019];[Guideline database:Cerebral infarction and cerebral hemorrhage] Available at: https://richtlijnendatabase.nl/richtlijn/herseninfarct_en_hersenbloeding... .
-
- Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann FJ, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN. ESC Scientific Document Group;ESC Committee for Practice Guidelines (CPG);ESC National Cardiac Societies 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J. 2018;39(3):213–260. doi: 10.1093/eurheartj/ehx419. - DOI - PubMed
-
- Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Muñoz D, Rosenhek R, Sjögren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL. ESC Scientific Document Group. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–2791. doi: 10.1093/eurheartj/ehx391. - DOI - PubMed
LinkOut - more resources
Full Text Sources